launch, of an Justin. Thank important of become these expressing option We support the the interacted potential the new field I from by epilepsy and few of demand treatment fact by wanted academic Epidiolex X,XXX Epidiolex we for stronger that to within centers epilepsy well months had believed the target to availability. encouraged XX% organization early are in seeing into to first level pleased we are you, commercial about of Sales has are how we see physicians. always epilepsy begin universe practice private that as to as the major both the Epidiolex coming date clinics. with
These by by attending of XXX% and on have support addition, extensive X have programs over supported sales speaker also these educational of Level organization. interactions been with physicians all broadcasts to series X the our an and been XXX events. called In launch epilepsy centers educational
approximately also channel an communication hosted patient have as local with represent events We organizations they of patient XXX within advocacy sharing communities. and important these
Turning to demand.
two out the the forms on November Through everyone new first remind Epidiolex commercial launch Xst Epidiolex received. physicians, months period, of the call, X,XXX dispensed over to launch the patient prescriptions. same our of to target of audience generated year. over Just December, physicians the date In of last enrollment XXX were for was two-month X,XXX
January of encouraged just of from November December are the to some was on be activity provide in activity XX, order it color short approximately in would in December time highly growth two-month this XXXX prescriber trends some Prescription by new shine thought level to January patient helpful in the initial on first We months. light XXXX the In over with XXX%. Xst selling two and enrollment period. we light investors to period beyond
two to to strong contributed January. in growth month-on-month have growth encouraged the but important are like We by to we'd point that factors this
eligible extent that that to patients commercial namely, new regulate hubs reimbursement launch bolus process a that in for Limited introductions, of payers patient the used is market timely month to January new the November in product of and the our to ability in a first coupled demand standard first the The enrollments with new some control block of created fashion, timeframe.
January discussion, I'd payor their in again, like another made known Building the get of year, causing to payer In the update prescriptions January. states, of patients in many on addition, initiatives. investors our bolus filled on Medicaid this to of coverage determination only
shared major Over the priorities our last with months, engaging payors. we have has been that with you one XX of
I channels, unusual and of This it the is mentioned commercial states determination. As onerous both prescriptions process plants Medicaid this period. market dispensed time institute they before not earlier, the to block or for a getting in new coverage to could during make a make
payers encouraged launch understood We however are for determination that for made coverage value very product. a proposition into have early have the Epidiolex the and the many
we win the Scripts a the Express we payers, brand to first a in our in which December of with number or at all Epidiolex on as the States, with label. either placed commercial If Turning building payors November covered national XX% determinations. PA coverage preferred favorable formulary, XX% their United make of commercial lives no now of all early with seen and in determination major look lives PA on coverage lives have have January a to
a launched on have the other for either payors simple our And work a and Service State with of in requirement. of network in with that a briefly a coverage with reducing or the made. our made XXXX again set a XX% and specialty is improvements such Managed Medicaid to as hub did AED them label. to states XX% our XX% January, have determination, PA of failure on happy the XX% requirement new of thus XX% Fee are distribution goal covered made enrollments as Epidiolex November lives PA as on PA be Turning in January, our to to a not far of work some of over or I we the decision to coverage end providers, with for closed five second want access and many of for those with have of uncovered balance where be can touch end pharmacies. coverage, label. Overall, a some the vendor, are a triage's open have Medicaid, met, enhancements. The or another require model one physician lives coverage patient payor of to We coverage a determination, including but burden with
I efficiency, move needed became that As speed pharmacies in hub and specialty the meaningful earlier, the clear mentioned first process. PA improve the the through generated we the needed to to at the which demand due both to with month, it
The greater During efficiency now of community-based including our enhancements, the November, impact of four weeks for reside specialty it significant, epilepsy based pharmacy addition, i.e. product. somewhat medical and key some have early specialty distribution to other with being we within opening to in a in of that these than triage number We about cases key network pharmacies, SPs up dispensing December fill institutional is XXX. center, to taking some major and XX locations academic sites has the caregivers was opened CVS enhancements a specialty close bringing physicians. patients, time a many hubs and pharmacies, also Walgreen been number up a of frame, a significantly instituted including number centers, which benefit and improving
changes is overall model meaningfully the fill. will to retail of takes caregivers time serve been time believe or addition, known dispense prescription We the years. to patients needs the physicians, In these over as effect has and it the from what coming of light of reduce to presentation the this
with concomitant They to disease, are their young likely we feedback, indicated also Dravet efficacy milligrams LGS drugs, titrating XX the the that have to titrating higher Epidiolex complex number focused Looking guidelines, the patients see qualitatively to and and the doses. the observing are and prescriber nature up syndrome titrate to base before the first. they per effect of at of clinicians on kilogram due label that
months revenue. early as which titration these informed you model are So is early prescriptions also
XX% approximately for to to to awareness that open of exhibited been of that vast having found to healthcare been know you by are existing recent product. patients they Epidiolex LGS FDA these XXX the actively course many second assess their of sense complete interest. done access high early We've are running most gain is XXX This providers we a have HCPs be extension and quarter We patients initial transition commercial over or primary I expected patients. with the now migrating own research of by expanded prescribing caregivers on Epidiolex heard label perspectives. indicated in XX% of next Epidiolex. physician and of the months. being approval our launch HCP waves since for patients was HCPs refractory controlled What end observations already immediate are I similar their asked to XX% highly Epidiolex candidates weekly these have these with increase consistent about adequately basis. specifically what you that three have surveys. introduction. commercial hope with in about expecting few characterized with being asked prescribed the respondents as XX% Dravet and for that's making majority Epidiolex and or a
Our healthcare as marketing in an caregivers continue and the marketplace, sales resources array medical be they to teams and providers, delivering support and educate extensive patients. materials very to active team information of the
a hosts objective team and empathetic information comprehensive and dedicated being in-house caring information medical of consistent This is for support the an Our quality, providing widely high manner. with resource utilized. both center in and HCPs caregivers
importantly successful early by as and experiencing. also and state caregivers for encouraged and support we physicians US patients metrics and spontaneous and we meaningful interest seizures Epidiolex been our the plan we believe commercial positive payors that am heartened are is of team that US. both the are the important today Epidiolex significant most very have favorable Finally our by particular In is perhaps, launch in made patients, executing we've coverage in launch commercial I that and these encouraged belief world-class high physicians of we and determinations have the The difference, effectively. reports Overall, to from progress. patients' received lives share level reduction of Epidiolex year the by are making a the number and in here that the of making number from Europe,
Chris? ask Chris Let an COO, GW's commercialization. Europe on me Tovey, update now to provide
